Your browser is no longer supported. Please, upgrade your browser.
Settings
AVIR Aviragen Therapeutics, Inc. daily Stock Chart
AVIR [NASD]
Aviragen Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.76 Insider Own1.18% Shs Outstand38.65M Perf Week19.67%
Market Cap27.98M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float38.19M Perf Month27.02%
Income-29.40M PEG- EPS next Q-0.28 Inst Own38.00% Short Float0.32% Perf Quarter36.19%
Sales8.90M P/S3.14 EPS this Y-15.70% Inst Trans-9.28% Short Ratio0.34 Perf Half Y9.70%
Book/sh0.48 P/B1.51 EPS next Y- ROA-57.00% Target Price4.17 Perf Year-54.18%
Cash/sh1.00 P/C0.72 EPS next 5Y- ROE-109.40% 52W Range0.43 - 2.00 Perf YTD-41.14%
Dividend- P/FCF- EPS past 5Y6.50% ROI-146.30% 52W High-63.80% Beta0.00
Dividend %- Quick Ratio6.80 Sales past 5Y-9.70% Gross Margin- 52W Low67.98% ATR0.05
Employees21 Current Ratio6.80 Sales Q/Q-80.00% Oper. Margin- RSI (14)66.34 Volatility10.62% 7.92%
OptionableNo Debt/Eq0.02 EPS Q/Q15.70% Profit Margin- Rel Volume0.66 Prev Close0.72
ShortableYes LT Debt/Eq0.01 EarningsSep 13 AMC Payout- Avg Volume365.24K Price0.72
Recom3.00 SMA2013.70% SMA5019.06% SMA200-4.58% Volume0 Change0.00%
Feb-15-17Downgrade H.C. Wainwright Buy → Neutral
Feb-14-17Downgrade Ladenburg Thalmann Buy → Neutral
Sep-09-17 12:00AM  ETFs with exposure to Aviragen Therapeutics, Inc. : September 9, 2017 Capital Cube
Sep-08-17 05:17PM  Aviragen Therapeutics, Inc. :AVIR-US: Earnings Analysis: Q4, 2017 By the Numbers : September 8, 2017 Capital Cube
Sep-07-17 10:06AM  Aviragen Therapeutics, Inc. :AVIR-US: Earnings Analysis: 2017 By the Numbers : September 7, 2017 Capital Cube
Aug-31-17 04:01PM  Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results GlobeNewswire
Jul-17-17 08:00AM  Bio-Path Holdings Appoints Mark Colonnese to its Board of Directors GlobeNewswire
Jun-30-17 02:41PM  ETFs with exposure to Aviragen Therapeutics, Inc. : June 30, 2017 Capital Cube
Jun-19-17 02:57PM  ETFs with exposure to Aviragen Therapeutics, Inc. : June 19, 2017 Capital Cube
May-31-17 12:21PM  ETFs with exposure to Aviragen Therapeutics, Inc. : May 31, 2017 Capital Cube
May-11-17 04:12PM  ETFs with exposure to Aviragen Therapeutics, Inc. : May 11, 2017 Capital Cube
May-10-17 10:34AM  Aviragen Therapeutics, Inc. :AVIR-US: Earnings Analysis: Q3, 2017 By the Numbers : May 10, 2017 Capital Cube
May-04-17 07:00AM  Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results GlobeNewswire
Apr-05-17 04:21PM  ETFs with exposure to Aviragen Therapeutics, Inc. : April 5, 2017 Capital Cube
08:15AM  Blog Coverage Aviragen to Explore Strategic Alternatives; Cuts Headcount by 25% Accesswire
Apr-04-17 06:00AM  Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update GlobeNewswire -5.79%
Apr-03-17 04:31PM  AVIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Mar-21-17 11:33AM  Aviragen Therapeutics, Inc. :AVIR-US: Earnings Analysis: Q2, 2017 By the Numbers : March 21, 2017 Capital Cube
Feb-15-17 07:10AM  Aviragen Therapeutics downgraded by H.C. Wainwright
Feb-14-17 10:45AM  Aviragen Tanks on Second Antiviral Drug Failure Investopedia -37.22%
Feb-13-17 04:01PM  Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir GlobeNewswire -5.26%
Feb-10-17 01:04PM  AVIRAGEN THERAPEUTICS, INC. Financials
Feb-06-17 03:11PM  AVIRAGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Feb-03-17 01:34PM  AVIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
Feb-02-17 04:30PM  Aviragen Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today
04:01PM  Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results GlobeNewswire
03:02PM  Aviragen Hits 52-Week Low After Drug Fails Trial Investopedia
11:26AM  AVIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:07AM  Q2 2017 Aviragen Therapeutics Inc Earnings Release - After Market Close
Feb-01-17 04:30PM  Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585 GlobeNewswire -5.38%
Jan-26-17 04:01PM  Aviragen Therapeutics to Host Conference Call to Report Second Quarter Fiscal Year 2017 Financial Results on February 2, 2017 GlobeNewswire
09:06AM  Aviragen Therapeutics Inc (AVIR) Could Start To Move Near Term Insider Monkey
09:06AM  Aviragen Therapeutics Inc (AVIR) Could Start To Move Near Term at Insider Monkey
Jan-09-17 10:59AM  AVIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
06:00AM  Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan GlobeNewswire
Nov-23-16 12:01PM  Edited Transcript of AVIR earnings conference call or presentation 3-Nov-16 8:30pm GMT Thomson Reuters StreetEvents +6.62%
Nov-10-16 02:21PM  AVIRAGEN THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Nov-09-16 04:01PM  Aviragen Therapeutics to Present at Stifel 2016 Healthcare Conference GlobeNewswire +12.40%
Nov-08-16 04:18PM  AVIRAGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Nov-07-16 11:40AM  Aviragen Therapeutics, Inc. :AVIR-US: Earnings Analysis: Q1, 2017 By the Numbers : November 7, 2016 Capital Cube
11:40AM  Aviragen Therapeutics, Inc. :AVIR-US: Earnings Analysis: Q1, 2017 By the Numbers : November 7, 2016
Aviragen Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect patients worldwide. Its product candidates that are in clinical development includes Vapendavir, a potent antiviral capsid binder that is in Phase IIb SPIRITUS trials for human rhinovirus upper respiratory infections in moderate-to-severe asthmatics; BTA585, an oral fusion protein inhibitor, which is in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, an antiviral treatment that is in Phase II development for condyloma caused by human papillomavirus types 6 and 11. The company also has a preclinical RSV non-fusion inhibitor program. It has a research and license agreement with GlaxoSmithKline for the development and commercialization of zanamivir, a neuraminidase inhibitor (NI) to prevent and treat influenza; and collaboration and license agreement with Daiichi-Sankyo for the development of Laninamivir octanoate, an NI for the treatment of influenza. The company was formerly known as Biota Pharmaceuticals, Inc. and changed its name to Aviragen Therapeutics, Inc. in April 2016 to reflect the strategic shift from the organization's prior focus on drug discovery and early-stage licensing to clinical development of next generation direct-acting antivirals to treat infections. Aviragen Therapeutics, Inc. is headquartered in Alpharetta, Georgia.